ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform ...

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MaxCyte. Analysts have given MaxCyte a total of 1 ratings, ...

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next ...

MaxCyte Inc. (NASDAQ:MXCT) reported its first-quarter 2025 earnings, showcasing a stronger-than-expected performance. The company posted a revenue of $10.4 million, surpassing the forecasted $9.05 ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next ...